snrnp35 Antibody

Overview of SNRNP35 Antibody

The SNRNP35 antibody targets the SNRNP35 protein, which facilitates the splicing of minor introns through its role in the U12-type spliceosome . This antibody is produced in rabbits using a recombinant fusion protein immunogen corresponding to amino acids 1–150 of human SNRNP35 . Key attributes include:

Role in mRNA Splicing and Disease Research

SNRNP35 contains an RNA recognition motif and Arg/Asp-rich domains, enabling its interaction with spliceosomal components . Dysregulation of splicing mechanisms involving SNRNP35 is implicated in:

• Cancer: Aberrant splicing contributes to oncogenic transformations, with spliceosome components serving as potential therapeutic targets .

• Genetic Disorders: Mutations in splicing factors are linked to developmental anomalies and neurodegenerative diseases .

Studies using SNRNP35 antibodies have validated its nuclear localization and overexpression in tissues like the brain (e.g., mouse brain) . Knockdown experiments in cell models highlight its essential role in maintaining spliceosome integrity .

Key Findings from Antibody-Based Studies

• Western Blot: Detects SNRNP35 at 35 kDa in human and mouse lysates (e.g., U-87MG glioblastoma cells) .

• Immunohistochemistry: Localizes SNRNP35 in nuclear compartments of formalin-fixed paraffin-embedded tissues .

• Functional Assays: CRISPR/Cas9 knockout models demonstrate reduced cell proliferation and tumorigenesis, underscoring SNRNP35’s role in cancer progression .

Future Directions

SNRNP35 antibodies are pivotal for:

• Mapping spliceosome dynamics in rare diseases.

• Developing RNA-splicing-targeted therapies for cancers .

• High-throughput screens to identify splicing-related biomarkers.